Premium
Low‐dose cladribine for symptomatic hairy cell leukaemia
Author(s) -
Juliusson Gunnar,
Lenkei Rodica,
Tjønnfjord Geir,
Heldal Dag,
Liliemark Jan
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb08377.x
Subject(s) - cladribine , cytopenia , medicine , leukopenia , hairy cell leukemia , gastroenterology , toxicity , leukemia , bone marrow
Cladribine is an effective therapy for hairy cell leukaemia (HCL), but the standard regime is frequently complicated by neutropenic fever and prolonged T‐cell depression. We studied 102 patients with active HCL following treatment with various doses of cladribine given for 7 d. Two patients received 1 mg cladribine/m 2 /d without toxicity or effect. Eight subsequent patients received 2 mg cladribine/m 2 /d, and normalized cytopenia as quickly as 94 control patients receiving a standard dose (3.4mg/m 2 or 0.085 mg/kg), with significantly less lymphopenia and a similar complete remission rate.